Molecular Targeted Therapy Market Reaches $107.64 Billion In 2026: Key Developments Shaping Expansion
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Molecular Targeted Therapy Market Revenue Outlook: What CAGR Lies Ahead Through 2030?
The molecular targeted therapy market has experienced substantial growth in recent years. This market is projected to expand from $71.64 billion in 2025 to $77.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.7%. The observed expansion in past periods can be credited to advancements in cancer genomics research, the development of monoclonal antibodies, numerous oncology drug approvals, the establishment of hospital oncology centers, and the broadening of clinical trials.
The molecular targeted therapy market is anticipated to experience robust expansion over the next few years, projected to reach $107.64 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 8.4%. This expected growth during the forecast period can be attributed to several factors, including the increasing prevalence of personalized cancer treatments, the broader adoption of next-generation sequencing, advancements in AI-driven drug discovery, the rising global oncology burden, and improved reimbursement for targeted therapies. Significant trends for the forecast period encompass the wider application of precision oncology, a greater uptake of biomarker-based therapies, the expansion of pipelines for targeted cancer drugs, the integration of companion diagnostics, and an increasing utilization of combination targeted therapies.
Get A Free Sample Report With In-Depth Market Insights:
Molecular Targeted Therapy Market Demand Drivers: What’s Powering Industry Growth?
The growth of the molecular targeted therapy market is anticipated to be fueled by the increasing prominence of personalized medicine. This healthcare approach customizes treatment and prevention based on an individual’s unique genetic profile, lifestyle, and environmental factors. Personalized medicine is gaining traction due to the greater availability of genetic data, enabling therapies specifically designed for individual genomes, leading to enhanced effectiveness and fewer side effects. It supports molecular targeted therapy by analyzing a patient’s tumor for specific genetic mutations or biomarkers, which then guides the selection of therapies that directly target these abnormalities. This methodology enhances treatment accuracy and minimizes harm to healthy tissues. For example, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, a significant rise from 6 in 2022. Consequently, the expansion of personalized medicine is a key driver for the molecular targeted therapy market.
Molecular Targeted Therapy Market Segment Landscape And Growth Outlook
The molecular targeted therapy market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies, Small Molecule Inhibitors, Gene Therapy, Cell Therapy
2) By Mode Of Administration: Oral, Injectable, Topical, Intravenous
3) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Other Applications
4) By End-User: Hospitals, Clinics, Research Laboratories, Diagnostic Centers
Subsegments:
1) By Monoclonal Antibodies: Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Small Molecule Inhibitors: Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly Adenosine Diphosphate (ADP) Ribose Polymerase (PARP) Inhibitors, Mechanistic Target Of Rapamycin (mTOR) Inhibitors
3) By Gene Therapy: Viral Vector-Based Gene Therapy, Non-Viral Vector-Based Gene Therapy, Genome Editing
4) By Cell Therapy: Chimeric Antigen Receptor T-Cell Therapy, T-Cell Receptor (TCR) Therapy, Tumor-Infiltrating Lymphocytes (TILs) Therapy, Dendritic Cell Therapy
Molecular Targeted Therapy Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the molecular targeted therapy market are prioritizing the development of advanced products, such as small molecule inhibitors, to enhance patient outcomes for various cancers and chronic illnesses. Small molecule inhibitors are minute compounds capable of readily penetrating cells and blocking specific proteins that contribute to disease progression. For example, in January 2025, Amgen Inc., a US-based pharmaceutical company, launched Lumakras (sotorasib) in conjunction with Vectibix (panitumumab), following its approval from the US Food and Drug Administration (FDA), a US-based government organization. This therapy is intended for adult patients with KRAS G12C-mutated metastatic colorectal cancer who have previously undergone fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, as determined by an FDA-approved diagnostic test. This approval was granted based on the Phase 3 CodeBreaK 300 trial, which indicated that the combination substantially more than doubled progression-free survival when compared to the investigated standard of care, making it the first targeted therapy to demonstrate such a benefit in this patient group resistant to prior chemotherapy.
Molecular Targeted Therapy Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the molecular targeted therapy market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Amgen Inc., Regeneron Pharmaceuticals, Vertex Pharmaceuticals Incorporated, Novartis AG, Incyte Corporation, Exelixis Inc., IDEAYA Biosciences Inc., Prelude Therapeutics Incorporated, Gamida Cell Ltd., Adaptimmune Therapeutics plc, Engine Biosciences Pte. Ltd., Krystal Biotech Inc., Sotio Biotech a.s., Cybrexa Therapeutics Inc.
View The Full Molecular Targeted Therapy Market Report:
Molecular Targeted Therapy Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the molecular targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the molecular targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
